BCL2L1 and melanoma: As such, MCL-1 inhibitors strongly sensitized BRAF and NRAS driven melanoma cell lines to inhibition of the RAF-MEK-ERK pathway, more so than inhibitors of BCL-2/BCL-XL, and more so than in ERK pathway-driven colorectal cancer cell lines.